Simple prognostic markers in patients with hematological malignancies and coronavirus disease 2019 infection: Single-center experience

The Egyptian Journal of Haematology

article

Nahed M. Rakha¹  Dalia Abdel E. Mohammed²  Noha B. Hassan³  Nour El Hoda H. Abdalla¹ 

[1] Clinical Hematology and Bone Marrow Transplantation Unit, Faculty of Medicine, Ain Shams University;Department of Chest, Faculty of Medicine, Ain Shams University;Department of Clinical Pathology, Faculty of Medicine, Ain Shams University

关键词: coronavirus disease 2019;    biomarkers;    lymphocyte-to-neutrophil ratio;    neutrophil-to-monocyte ratio;   

DOI  :  10.4103/ejh.ejh_31_22

来源: Medknow

【 摘 要 】

Background Coronavirus disease 2019 (COVID-19) pandemic rapidly spread from China to other countries. The clinical features of patients with COVID-19 have revealed a number of potential biochemical markers associated with in-hospital mortality. Numerous studies have proposed the use of hematological markers that seem to associate with increased severity and mortality in patients with COVID-19. Aim To evaluate the prognostic value of some hematological parameters and inflammatory biomarker effect on overall survival (OS) and mortality on patients with hematological malignancies infected with COVID-19. Patients and methods A cross-sectional study of 50 adult Egyptian patients with different hematological malignancies were recruited from Clinical Hematology Department, Ain Shams University Hospital, over the period from December 2020 to October 2021. Results The mean of neutrophil-to-monocyte ratio (NMR) was 0–110 and median interquartile range 7.40 (3.0–16.67)×103/µl and there is significant correlation between NMR and OS with P value of 0.031, there is significant correlation between OS of those patients and D-dimer, ferritin, hematocrit, and red-blood cell count. Conclusion There are simple, easy, and rapid tests such as the NMR, inflammatory biomarkers (ferritin and D-dimer), and some hematological parameters (hematocrit and red blood cell) that have prognostic value on OS and mortality on patients with hematological malignancies infected with COVID-19.

【 授权许可】

Unknown